Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

This is an early-phase study testing a new drug called ABT-101 in two groups: people with any advanced solid tumor (Phase 1b dose-finding), and people with non-small cell lung cancer (NSCLC) that has a specific HER2 mutation (Phase 2). **You may be eligible if...** - You are 20 or older (or the adult age in your country) - You have an advanced solid tumor (for Phase 1) or NSCLC with a confirmed HER2 mutation (for Phase 2) - You have measurable disease (for Phase 2) - You are in good functional health (ECOG 0–1 for Phase 1; 0–2 for Phase 2) - Your organ function is adequate **You may NOT be eligible if...** - You have active or untreated brain metastases - For Phase 2: you have previously been treated with EGFR or HER2-targeted therapies - You have serious active infections or received a live vaccine recently - You received prior cancer therapy within 28 days - You have a significant heart condition (QTcF ≥470 ms) - You have a gastrointestinal disorder that would prevent the drug from being absorbed Talk to your doctor to see if this trial is right for you.